News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
127 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (37443)
2025 (32181)
Month
January (2488)
February (2603)
March (3228)
April (2950)
May (3962)
June (3500)
July (2854)
August (3142)
September (3205)
October (3540)
November (3386)
December (2332)
Day
1 (247)
2 (234)
3 (123)
4 (6)
5 (2)
6 (157)
7 (294)
8 (215)
9 (227)
10 (147)
11 (6)
12 (2)
13 (213)
14 (201)
15 (161)
16 (149)
17 (68)
19 (2)
20 (132)
21 (113)
22 (70)
23 (4)
24 (6)
26 (9)
27 (154)
28 (186)
29 (127)
30 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Drug Development
Mind-Blowing: Amgen’s Aimovig Halves Length of Migraine Attacks in Phase III Study
Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half.
November 29, 2017
·
2 min read
·
Alex Keown
Deals
Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
November 29, 2017
·
3 min read
·
Mark Terry
Business
Troubled Otonomy Cuts Jobs, Ceases Programs Related to Otiprio
Otonomy said dropping the program and terminating the employees will provide a cash savings of more than $20M in 2018.
November 29, 2017
·
3 min read
·
Alex Keown
Business
Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
November 29, 2017
·
4 min read
Business
MedMira Reports 2017 Fourth Quarter and Year End Financial Results
Total product revenues recorded for FY2017 were $747,344 compared to $962,140 in FY2016.
November 29, 2017
·
2 min read
Job Trends
2018 Hiring Trends for Life Science Job Hunters
Here are five trends job hunters may see in the life sciences next year.
November 29, 2017
·
6 min read
·
Mark Terry
Genetown
2-Year Old Codiak Lands Another $76.5M, Bringing Its Total Raise to $168.5M
The company indicates it plans to use the proceeds from the latest financing to move its lead product candidates into clinical trials and to continue developing its exosome therapeutic platform.
November 29, 2017
·
3 min read
·
Mark Terry
BioForest
Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now
Omeros is getting a lot of love from investors and analysts these days.
November 29, 2017
·
3 min read
·
Mark Terry
Job Trends
bluebird to Hire at New In-House Manufacturing Facility in North Carolina
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
November 29, 2017
·
2 min read
·
Alex Keown
Biocartis Scores 80M Euros to Fund Expansion of Its Idylla Test Menu
The firm said it sold the shares at an issue price of €12.50 each, and that the total 6.4 million shares represent approximately 14.3 percent of its outstanding shares.
November 29, 2017
·
1 min read
1 of 13
Next